Health Care [ 4/12 ] | Biotechnology [ 11/75 ]
NASDAQ | Common Stock
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States.
The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study.
It is also involved in the development of various preclinical DR3-based bispecific antibodies for the treatment of patients with inflammatory bowel disease or other immune-mediated indications; and TRIM7, an oncology-focused program.
The company was incorporated in 2016 and is headquartered in Austin, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 17, 26 | -0.12 Increased by +67.57% | -0.13 Increased by +8.81% |
| Nov 6, 25 | -0.14 Increased by +57.58% | -0.14 Increased by +2.23% |
| Aug 14, 25 | -0.24 Increased by +42.86% | -0.24 Increased by +2.04% |
| Apr 30, 25 | -0.27 Increased by +27.03% | -0.28 Increased by +4.42% |
| Feb 26, 25 | -0.37 Increased by +9.76% | -0.32 Decreased by -16.06% |
| Nov 7, 24 | -0.33 Increased by +49.23% | -0.42 Increased by +21.43% |
| Aug 1, 24 | -0.42 Increased by +16.00% | -0.41 Decreased by -2.44% |
| May 2, 24 | -0.37 Increased by +24.49% | -0.45 Increased by +17.78% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 0.00 Decreased by -100.00% | -12.59 M Increased by +32.58% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 25 | 1.00 M Decreased by -66.63% | -10.06 M Increased by +39.69% | Decreased by -1.01 K% Decreased by -80.74% |
| Jun 30, 25 | 0.00 Decreased by -100.00% | -12.46 M Increased by +42.20% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 25 | 14.49 M Increased by +1.20 K% | -13.70 M Increased by +25.95% | Decreased by -94.55% Increased by +94.30% |
| Dec 31, 24 | 34.70 M Increased by +4.76 K% | -18.68 M Decreased by -5.61% | Decreased by -53.82% Increased by +97.83% |
| Sep 30, 24 | 3.00 M Increased by +336.88% | -16.68 M Increased by +39.45% | Decreased by -556.39% Increased by +86.14% |
| Jun 30, 24 | 1.61 M Increased by +704.50% | -21.55 M Decreased by -0.97% | Decreased by -1.34 K% Increased by +87.45% |
| Mar 31, 24 | 1.11 M Increased by +1.86 K% | -18.50 M Increased by +10.71% | Decreased by -1.66 K% Increased by +95.44% |